Diabetes: Safer PPARγ 3-targeted drugs on the horizon?

Nature Reviews Drug Discovery

Volumn 10, Issue 11, 2011, Pages 814-815

  Crunkhorn, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SERINE; SR 1664; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANTIDIABETIC ACTIVITY; BODY FAT; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG IDENTIFICATION; DRUG SAFETY; FRACTURE; HUMAN; INSULIN SENSITIVITY; LIPID STORAGE; MOLECULARLY TARGETED THERAPY; NOTE; OBESITY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIDE EFFECT;

EID: 80255126139     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3587     Document Type: Note

References (1)

1. Choi, J. H. et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477-481 (2011)